media – Page 246 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

635 million US dollars! Anmai Biological BCMA × CD3 Double Antibody Successfully Goes to Sea

On September 4th, Anmai Biotechnology announced that it has reached a licensing agreement with Vignette Bio for the T cell conjugation (TCE) molecule EMB-06 targeting BCMA. picture According to the agreement, Amway Bio will grant Vignette the exclusive right to develop and commercialize EMB-06 outside the Greater China region (including Chinese Mainland, Hong Kong, Macao and Taiwan), and Amway Bio will reserve the right of EMB-06 in the Greater China region. Anmai Biotechnology will receive a total down payment of $60 million in cash and Vignette equity, and will have the right to receive up to $575 million in milestone payments for development, listing, and commercialization, as well as revenue sharing based on net sales. EMB-06 is the first TCE molecule developed under the T cell conjugation platform of Anmai Biotechnology, which combines Anmai Biotechnology’s self-developed FIT Ig bispecific antibody platform and CD3 binding domain library, as well as Anmai ...
- Source: drugdu
- 318
- September 6, 2024
Mindray Medical Ranks as one of the Best Brand in China

On September 3rd, Interbrand, a global brand strategy management consulting and design company, released the “2024 China’s Best Brands Ranking”. Mindray Medical was selected and maintained a strong upward trend for the second consecutive year, ranking 34th on the list with a brand value of 11.541 billion yuan, an increase of 18% compared to last year. Under the dual tests of economic cycles and market competition, the total value of the brands listed in the “2024 China’s Best Brands Ranking” maintained a slight increase, reaching 3371.26 billion yuan, showing an overall stable trend. Among them, over 60% of brands have achieved value growth, demonstrating strong brand resilience and innovation drive, including Mindray Medical. It should be emphasized that Mindray Medical is also the top ranked medical device brand on this list. So, what exactly did Mindray Medical rely on to achieve this result? In the process of promoting the upward ...
- Source: drugdu
- 421
- September 6, 2024
Two innovative medical devices have been approved for market launch

On September 3rd, the National Medical Products Administration announced that it has recently approved the registration applications for two innovative products, the “Navigation Positioning Microwave Ablation System” of True Health (Zhuhai) Medical Technology Co., Ltd. (hereinafter referred to as “True Health Medical”) and the “Hepatitis B Virus Surface Antigen (HBsAg) Detection Kit (Chemiluminescence Method)” of Fuji Ruibiou Co., Ltd. (hereinafter referred to as “Fuji Ruibiou”). True Health Medical: International First Product Founded in 2018, True Health Medical is a national high-tech enterprise specializing in the research and production services of surgical robots. Based on artificial intelligence technology, it integrates intelligent robot systems into the diagnosis and treatment process through the close integration of industry, academia, research, and medicine, achieving a comprehensive medical technology system with precise puncture of soft tissue lesions throughout the body as a diagnostic and treatment method. Precise puncture is a means to deliver minimally invasive treatment ...
- Source: drugdu
- 438
- September 6, 2024
Zhifei Biological’s 23-valent Pneumococcal Vaccine Price Reduction of Nearly 30%, Another Vaccine Field Will Be Involved in the “Price War”?

September 3, Jilin Province Public Resources Trading Center issued a document that will Zhifei Biological 23-valent pneumococcal polysaccharide vaccine from the original 298/branch down to 209 yuan/branch, down 29.87%. The following day, the Jiangsu Provincial Public Resources Trading Center issued a notice that also reduced the vaccine from 298/branch to 209 yuan/branch. At the end of August last year, Zhifei Biological’s 23-valent pneumococcal polysaccharide vaccine was formally approved for marketing in China for the prevention of infectious diseases caused by pneumococcus bacteria in children aged 2 years and above and adults. According to the half-year report of Zhifei Biological 2024, the approved and issued volume of its 23-valent pneumonia vaccine was 160,000 doses from January to June this year. During the same period, the approved and issued volume of Merck Sharp & Dohme’s 23-valent pneumonia vaccine, for which Zhifei Bio is the agent, amounted to 845,000 units, a year-on-year increase ...
- Source: drugdu
- 446
- September 6, 2024
The victory of tens of billions of dollars, the revelation of the rise of the new vaccine elite

Before the new crown vaccine, Pfizer’s 13-valent pneumococcal vaccine was the world’s “king of vaccines”, with global sales of nearly 6 billion US dollars in 2018, far exceeding the second-place 9-valent HPV vaccine (3.15 billion US dollars). No one wants to miss such a big market. While domestic companies are still rolling up the 13-valent pneumococcal vaccine (PCV13), Vaxcyte is rolling up the price type upgrade. VAX-24 is a vaccine covering 24 virus types, while VAX-31 has rolled up 31 types. Of course, the 13-valent pneumococcal vaccine has brought epoch-making changes to the prevention of pneumonia. However, while the popularity of PCV13 has greatly increased, it has also brought new troubles: the replacement of virus types. Since the introduction of PCV13, the incidence of diseases caused by the serotypes included in the vaccine has decreased. However, there is a phenomenon called serotype replacement, that is, after widespread vaccination, the incremental ...
- Source: drugdu
- 486
- September 6, 2024
AstraZeneca China’s structure will be adjusted

According to various sources in the industry, AstraZeneca China’s biopharmaceutical business BBU and omnichannel business unit structure will undergo a series of adjustments on October 1 this year. AstraZeneca China’s biopharmaceutical business and omnichannel business unit will be officially merged to form a new AstraZeneca China biopharmaceutical business (BBU). Merge the respiratory inhalation business unit, respiratory atomization business unit and digestive business unit to form the respiratory digestive business unit; merge the biologics business unit, vaccines and immunotherapy, and autoimmune business unit; merge the biologics business unit, vaccines and immunotherapy, and autoimmune business unit to form the respiratory and autoimmune biopharmaceuticals, vaccines and immunotherapy business units. According to incomplete statistics, this is at least the third adjustment of AstraZeneca China this year. “Adjustment” seems to be the key to AstraZeneca China’s performance development. AstraZeneca once said that the new map will add momentum to the long-term development of its business. ...
- Source: drugdu
- 503
- September 6, 2024
【EXPERT Q&A】What are the six bases for the classification of import and export commodities?

Drugdu.com expert’s response: The six major bases for the classification of import and export commodities mainly include the following aspects: Ⅰ. The Harmonized System Convention on Commodity Nomenclature and Coding (HS Convention) Commodity Classification System: The classification of import and export commodities is first and foremost conducted under the commodity classification system of the Harmonized System Convention (abbreviated as HS Convention). This is an internationally recognized standard for commodity classification, used for coding and categorizing commodities in global trade. Ⅱ. Customs Tariff of the People’s Republic of China: The Customs Tariff serves as the fundamental document for China’s customs authorities to classify and levy taxes on import and export commodities. It provides detailed listings of tariff numbers and rates for various commodities, serving as a crucial basis for determining the coding and tariff rates of import and export commodities. Ⅲ. Explanatory Notes to the Customs Tariff of the People’s Republic ...
- Source: drugdu
- 387
- September 6, 2024
As a new upstart in the imaging industry, is its billion-dollar halo no longer there?

Recently, United Imaging Healthcare released its 2024 semi-annual report. In the first half of the year, United Imaging Healthcare’s revenue was 5.333 billion yuan, a year-on-year increase of 1.18%; it achieved a net profit attributable to the parent of 950 million yuan, a year-on-year increase of 1.33%; and a net profit attributable to the parent of 798 million yuan, a year-on-year increase of 1.39%. In the semi-annual report, the growth of United Imaging Healthcare slowed down, and based on this, the stock price has been falling. Now that the market value of United Imaging Healthcare is not guaranteed, how can the upstart break through? Founded in 2011, United Imaging Healthcare is committed to providing global customers with a full range of independently developed high-performance medical imaging diagnostic and treatment equipment, life science instruments, and innovative solutions covering the entire chain of “basic research-clinical research-medical transformation”. Since its listing on the ...
- Source: drugdu
- 310
- September 6, 2024
【EXPERT Q&A】Where to check pharmacovigilance data?

Drugdu.com expert’s response: Regarding the inquiry of pharmacovigilance data, you can access the following specific agencies: Ⅰ. National Medical Products Administration (NMPA) and Its Subsidiaries NMPA Official Website: Each year, the NMPA releases the “Annual Report on National Adverse Drug Reaction Monitoring,” which informs the public of the annual status of adverse drug reaction monitoring in China. These reports and related pharmacovigilance information can be found on the NMPA’s official website (nmpa.gov.cn). National Center for Adverse Drug Reaction Monitoring (NCADR): The NCADR regularly compiles and publishes domestic pharmacovigilance information, as well as international pharmacovigilance alerts. This information can also be accessed on the NMPA’s official website or the NCADR’s official website (cdr-adr.org.cn). Ⅱ. Local Governments and Agencies Some local governments or drug regulatory agencies may have established their own pharmacovigilance databases or information platforms. For instance, Shandong Province has the “Medication ‘Alert’ Platform,” which utilizes information technology to provide channels ...
- Source: drugdu
- 322
- September 5, 2024
Edge Medical Releases Remote Surgery System

The 18th Annual Meeting of Chinese Hospital Directors was grandly held in Wuhan, Hubei from August 30th to September 1st. During the grand event, Edge Medical® Heavy Release of Edge Cloud ® The remote surgery system has been fully launched, and the “Thousand Medical Alliance Membership Program” has been fully launched to build a new intelligent remote surgery network platform with real-time multi-point interconnection, fully demonstrating the exclusive remote technology advantages of low latency, high fidelity, strong guarantee, and cloud interconnection. Continuously leading remote surgery, setting a historical record Remote surgery breaks through the limitations of space on surgical procedures, allowing high-quality medical resources and advanced surgical techniques from central cities to be projected in real-time to remote areas. It has important significance in alleviating uneven distribution of medical resources and promoting the sharing of advanced surgical technologies. In recent years, Edge Medical® Jointly with the General Hospital of the ...
- Source: drugdu
- 465
- September 5, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.